Foto del docente

Andrea Ardizzoni

Professore ordinario

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Pubblicazioni

Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea, A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale, «FUTURE ONCOLOGY», 2022, 1027, pp. 1 - 5 [articolo]

Comito, Francesca; Pagani, Rachele; Grilli, Giada; Sperandi, Francesca; Ardizzoni, Andrea; Melotti, Barbara, Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma, «CANCERS», 2022, 14, pp. 1 - 24 [articolo]Open Access

Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F., Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data, «ANTI-CANCER DRUGS», 2022, 33, pp. e61 - e68 [articolo]

Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco, Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2022, 17, pp. 43 - 51 [articolo]Open Access

Pantaleo M.A.; Urbini M.; Schipani A.; Nannini M.; Indio V.; De Leo A.; Vincenzi B.; Brunello A.; Grignani G.; Casagrande M.; Fumagalli E.; Conca E.; Saponara M.; Gruppioni E.; Altimari A.; De Biase D.; Tallini G.; Ravegnini G.; Turchetti D.; Seri M.; Ardizzoni A.; Secchiero P.; Astolfi A., SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor, «FRONTIERS IN ONCOLOGY», 2022, 11, Article number: 778461, pp. 1 - 7 [articolo]

Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F., Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System, «AMERICAN JOURNAL OF CLINICAL DERMATOLOGY», 2022, 23, pp. 247 - 255 [articolo]

Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B., Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma, «EUROPEAN JOURNAL OF CANCER», 2021, 147, pp. 58 - 59 [articolo]

Goss G.D.; Cobo M.; Lu S.; Syrigos K.; Lee K.H.; Goker E.; Georgoulias V.; Isla D.; Morabito A.; Min Y.J.; Ardizzoni A.; Bender S.; Cseh A.; Felip E., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial, «ECLINICALMEDICINE», 2021, 37, Article number: 100940, pp. 1 - 9 [articolo]

Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A., Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab., «EUROPEAN JOURNAL OF CANCER», 2021, 150, pp. 99 - 107 [articolo]

De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A., Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach, «EUROPEAN JOURNAL OF CANCER», 2021, 143, pp. 75 - 77 [articolo]

Filippini D.M.; Gatti M.; Di Martino V.; Cavalieri S.; Fusaroli M.; Ardizzoni A.; Raschi E.; Licitra L., Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, «INTERNATIONAL JOURNAL OF CANCER», 2021, 149, pp. 675 - 683 [articolo]

Mollica, Veronica; Franceschini, Tania; Gruppioni, Elisa; Rizzo, Alessandro; Ricci, Costantino; Schiavina, Riccardo; Brunocilla, Eugenio; Ardizzoni, Andrea; Fiorentino, Michelangelo; Giunchi, Francesca; Massari, Francesco, Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 219, Article number: 153350, pp. 1 - 7 [articolo]

Pantaleo M.A.; Mandruzzato M.; Indio V.; Urbini M.; Nannini M.; Gatto L.; Schipani A.; Fiorentino M.; Franceschini T.; Ambrosini V.; Di Scioscio V.; Saponara M.; Ianni M.; Concetti S.; Altimari A.; Ardizzoni A.; Astolfi A., Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling, «FRONTIERS IN ONCOLOGY», 2021, 11, Article number: 633543, pp. 1 - 9 [articolo]Open Access

Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F., Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis, «IMMUNOTHERAPY», 2021, 13, pp. 783 - 793 [articolo]

Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L., Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer, «NPJ BREAST CANCER», 2021, 7, Article number: 82, pp. 1 - 9 [articolo]